Postoperative adjuvant therapy for patients with resected non-small cell lung cancer

Still controversial after all these years

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Patients with clinical stage I and II non-small cell lung cancer (NSCLC) generally are considered candidates for surgical resection, with cure rates as high as 80% reported for some subsets. Locoregional and systemic adjuvant therapies have been evaluated in patients with lymph node involvement or pathologic T3 status, although considerable controversy regarding an appropriate standard of care continues to exist. Several trials have evaluated postoperative radiation therapy, the majority of which suggest that overall survival may be only minimally improved with this adjuvant therapy, but local failure is probably reduced. Trials evaluating the role of adjuvant chemotherapy have been few, often enrolling small numbers of patients. Several recent reviews summarizing the results of these trials suggest that, although some adjuvant chemotherapy regimens may have biological activity, results have not been consistent, and further study is warranted for regimens that include newer chemotherapy agents. CNS relapse is one of the most common sites of metastasis in NSCLC, and prophylactic cranial irradiation (PCI) has been evaluated in a number of trials to reduce the risk of local failure at this site. Data from these trials strongly suggest that a prospective trial of PCI in patients with NSCLC at high risk for isolated CNS relapse is warranted. Future clinical trials evaluating new radiographic, immunologic, and molecular technologies for early detection of second primary tumors also should be considered, particularly in patients with resected T1N0M0 lesions.

Original languageEnglish (US)
Pages (from-to)110S-118S
JournalCHEST
Volume117
Issue number4 SUPPL. 1
DOIs
StatePublished - Jan 1 2000

Fingerprint

Non-Small Cell Lung Carcinoma
Cranial Irradiation
Adjuvant Chemotherapy
Therapeutics
Recurrence
Standard of Care
Radiotherapy
Lymph Nodes
Clinical Trials
Neoplasm Metastasis
Technology
Drug Therapy
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{cd8ae85bd68c45b3bf9c6047e792718c,
title = "Postoperative adjuvant therapy for patients with resected non-small cell lung cancer: Still controversial after all these years",
abstract = "Patients with clinical stage I and II non-small cell lung cancer (NSCLC) generally are considered candidates for surgical resection, with cure rates as high as 80{\%} reported for some subsets. Locoregional and systemic adjuvant therapies have been evaluated in patients with lymph node involvement or pathologic T3 status, although considerable controversy regarding an appropriate standard of care continues to exist. Several trials have evaluated postoperative radiation therapy, the majority of which suggest that overall survival may be only minimally improved with this adjuvant therapy, but local failure is probably reduced. Trials evaluating the role of adjuvant chemotherapy have been few, often enrolling small numbers of patients. Several recent reviews summarizing the results of these trials suggest that, although some adjuvant chemotherapy regimens may have biological activity, results have not been consistent, and further study is warranted for regimens that include newer chemotherapy agents. CNS relapse is one of the most common sites of metastasis in NSCLC, and prophylactic cranial irradiation (PCI) has been evaluated in a number of trials to reduce the risk of local failure at this site. Data from these trials strongly suggest that a prospective trial of PCI in patients with NSCLC at high risk for isolated CNS relapse is warranted. Future clinical trials evaluating new radiographic, immunologic, and molecular technologies for early detection of second primary tumors also should be considered, particularly in patients with resected T1N0M0 lesions.",
author = "{Wagner Jr.}, Henry",
year = "2000",
month = "1",
day = "1",
doi = "10.1378/chest.117.4_suppl_1.110S",
language = "English (US)",
volume = "117",
pages = "110S--118S",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4 SUPPL. 1",

}

Postoperative adjuvant therapy for patients with resected non-small cell lung cancer : Still controversial after all these years. / Wagner Jr., Henry.

In: CHEST, Vol. 117, No. 4 SUPPL. 1, 01.01.2000, p. 110S-118S.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Postoperative adjuvant therapy for patients with resected non-small cell lung cancer

T2 - Still controversial after all these years

AU - Wagner Jr., Henry

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Patients with clinical stage I and II non-small cell lung cancer (NSCLC) generally are considered candidates for surgical resection, with cure rates as high as 80% reported for some subsets. Locoregional and systemic adjuvant therapies have been evaluated in patients with lymph node involvement or pathologic T3 status, although considerable controversy regarding an appropriate standard of care continues to exist. Several trials have evaluated postoperative radiation therapy, the majority of which suggest that overall survival may be only minimally improved with this adjuvant therapy, but local failure is probably reduced. Trials evaluating the role of adjuvant chemotherapy have been few, often enrolling small numbers of patients. Several recent reviews summarizing the results of these trials suggest that, although some adjuvant chemotherapy regimens may have biological activity, results have not been consistent, and further study is warranted for regimens that include newer chemotherapy agents. CNS relapse is one of the most common sites of metastasis in NSCLC, and prophylactic cranial irradiation (PCI) has been evaluated in a number of trials to reduce the risk of local failure at this site. Data from these trials strongly suggest that a prospective trial of PCI in patients with NSCLC at high risk for isolated CNS relapse is warranted. Future clinical trials evaluating new radiographic, immunologic, and molecular technologies for early detection of second primary tumors also should be considered, particularly in patients with resected T1N0M0 lesions.

AB - Patients with clinical stage I and II non-small cell lung cancer (NSCLC) generally are considered candidates for surgical resection, with cure rates as high as 80% reported for some subsets. Locoregional and systemic adjuvant therapies have been evaluated in patients with lymph node involvement or pathologic T3 status, although considerable controversy regarding an appropriate standard of care continues to exist. Several trials have evaluated postoperative radiation therapy, the majority of which suggest that overall survival may be only minimally improved with this adjuvant therapy, but local failure is probably reduced. Trials evaluating the role of adjuvant chemotherapy have been few, often enrolling small numbers of patients. Several recent reviews summarizing the results of these trials suggest that, although some adjuvant chemotherapy regimens may have biological activity, results have not been consistent, and further study is warranted for regimens that include newer chemotherapy agents. CNS relapse is one of the most common sites of metastasis in NSCLC, and prophylactic cranial irradiation (PCI) has been evaluated in a number of trials to reduce the risk of local failure at this site. Data from these trials strongly suggest that a prospective trial of PCI in patients with NSCLC at high risk for isolated CNS relapse is warranted. Future clinical trials evaluating new radiographic, immunologic, and molecular technologies for early detection of second primary tumors also should be considered, particularly in patients with resected T1N0M0 lesions.

UR - http://www.scopus.com/inward/record.url?scp=0343673916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343673916&partnerID=8YFLogxK

U2 - 10.1378/chest.117.4_suppl_1.110S

DO - 10.1378/chest.117.4_suppl_1.110S

M3 - Article

VL - 117

SP - 110S-118S

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4 SUPPL. 1

ER -